

7 October 2024 Sydney, Australia

Brain Injury Program GLP Studies Further Update 6

Highlights:

- *In vivo* micronucleus study completed providing further data to support safety of Nyrada's lead Brain Injury drug candidate NYR-BI03.
- Study was completed under Good Laboratory Practice (GLP) conditions.
- Nyrada remains on track to commence first in-human Phase I clinical trial for NYR-BI03 in late CY2024.

Nyrada Inc (ASX:NYR) ("Nyrada or "Company"), a drug development company specialising in novel small molecule therapeutics provides an update on its Brain Injury program Good Laboratory Practice (GLP) studies.

Nyrada today announces the successful completion of an *in vivo* micronucleus study for its lead drug candidate, NYR-BI03. This study, performed in rats and conducted under GLP conditions, assessed whether NYR-BI03 causes genetic damage. There was no increase in markers of genotoxicity in treated animals compared with control treated animals.

NYR-BI03 is a first-in-class neuroprotection treatment being developed for both stroke and traumatic brain injury (TBI). In February 2024, the Company announced preclinical stroke study results showing NYR-BI03 achieved a statistically significant neuroprotective effect, rescuing 42% of brain tissue in the penumbra region of treated animals.

In October 2024, Nyrada also announced the results of a preclinical coronary heart disease study. This study demonstrated that NYR-BI03 conferred a statistically significant 86% cardioprotection effect following myocardial ischemia-reperfusion injury. NYR-BI03 also demonstrated superior efficacy to Captopril, an FDA-approved therapy.

Subject to satisfactory completion of all GLP studies, Nyrada will submit a Human Research Ethics Application with the expectation of commencing its first in human Phase I clinical trial in late 2QFY2025 (quarter ending December 2024).

Nyrada Inc. Level 3, 828 Pacific Highway, Gordon NSW 2072 ARBN 625 401 818

GLP Study	Reported
AMES	• 16 July 2024
hERG	• 16 July 2024
Rat CNS	• 06 August 2024
Rat Respiratory	• 20 August 2024
Dog cardiovascular safety	• 09 September 2024
14-day Dog Toxicology	• 27 September 2024
In vivo micronucleus	• 7 October 2024
14-day Rat Toxicology	[redacted]
In vitro micronucleus	

-ENDS-



About Nyrada Inc

Nyrada is a drug discovery and development company specialising in novel small molecule therapies. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a drug to treat brain injury, specifically traumatic brain injury and stroke, and a cholesterol lowering drug. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

Investor & Corporate Enquiries:
Dimitri Burshtein
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: david.franks@automicgroup.com.au

Media Enquiries:
Catherine Strong
Sodali & Co
T: 02 8234 0111
E: catherine.strong@sodali.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.